About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker FATE · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Sep 14, 2026A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
NCT07570862 · Lupus Nephritis, Systemic Lupus Erythematosus
FT819
FATE
Fate Therapeutics
Phase 2Recruiting53Jul 1, 2029Registry ↗
Sep 2, 2026FT839 in Autoimmune Diseases
NCT07800871 · ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory M…
FT839
FATE
Fate Therapeutics
Phase 1/2Recruiting446Oct 2028Registry ↗
Sep 2, 2026FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Soli…
NCT07216105 · Non-Small Cell Lung Cancer, Colorectal Cancer
FT836, Cetuximab
FATE
Fate Therapeutics
Phase 1Recruiting119Jan 2028Registry ↗
May 22, 2026A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
NCT06308978 · Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Va…
FT819, Fludarabine
FATE
Fate Therapeutics
Phase 1Recruiting244Sep 30, 2027Registry ↗
Mar 19, 2026FT819 in Subjects With B-cell Malignancies
NCT04629729 · Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
FT819, Cyclophosphamide
FATE
Fate Therapeutics
Phase 1Active, not recruiting54Jun 18, 2025Registry ↗
Dec 12, 2025FT576 in Subjects With Multiple Myeloma
NCT05182073 · Multiple Myeloma, Myeloma
FT576 (Allogenic CAR NK cells with BCMA expression), Cyclop…
FATE
Fate Therapeutics
Phase 1Completed31Sep 20, 2024Registry ↗
Dec 9, 2025FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Sol…
NCT06241456 · Advanced Solid Tumor
FT825, Fludarabine
FATE
Fate Therapeutics
Phase 1Recruiting351May 1, 2029Registry ↗
Aug 22, 2025FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
NCT05950334 · Relapsed/Refractory B-Cell Lymphoma
FT522, Rituximab
FATE
Fate Therapeutics
Phase 1Completed20Jun 6, 2025Registry ↗
Oct 26, 2023FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
NCT04245722 · Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
FT596, Cyclophosphamide
FATE
Fate Therapeutics
Phase 1Terminated98Sep 27, 2023Registry ↗
Oct 26, 2023FT516 in Subjects With Advanced Hematologic Malignancies
NCT04023071 · Acute Myelogenous Leukemia, B-cell Lymphoma
FT516, Rituximab
FATE
Fate Therapeutics
Phase 1Terminated72Oct 23, 2023Registry ↗
Sep 21, 2023FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
NCT05395052 · Non Small Cell Lung Cancer, Colorectal Cancer
FT536, Cyclophosphamide
FATE
Fate Therapeutics
Phase 1Terminated5Aug 11, 2023Registry ↗
Sep 21, 2023FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
NCT05069935 · Solid Tumor, Adult
FT538, Cyclophosphamide
FATE
Fate Therapeutics
Phase 1Terminated16Aug 11, 2023Registry ↗
Sep 21, 2023FT538 in Subjects With Advanced Hematologic Malignancies
NCT04614636 · Acute Myeloid Leukemia, AML, Adult
FT538, Cyclophosphamide
FATE
Fate Therapeutics
Phase 1Terminated42Jul 13, 2023Registry ↗
Sep 21, 2023FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
NCT04551885 · Solid Tumor, Adult
FT516, Avelumab
FATE
Fate Therapeutics
Phase 1Terminated12Aug 11, 2023Registry ↗
Sep 21, 2023Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500…
NCT04106167 · Advanced Solid Tumor, Lymphoma
Allogeneic natural killer (NK) cell
FATE
Fate Therapeutics
—Terminated20Aug 11, 2023Registry ↗
Jul 6, 2023FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
NCT05934097 · Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hod…
FT596, Cyclophosphamide
FATE
Fate Therapeutics
Phase 1Withdrawn0May 2026Registry ↗
May 1, 2023FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced…
NCT03841110 · Advanced Solid Tumors, Lymphoma
FT500, Nivolumab
FATE
Fate Therapeutics
Phase 1Completed37Nov 15, 2022Registry ↗
Feb 8, 2023Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
NCT02743351 · Hematologic Malignancies, Acute Myeloid Leukemia
ProTmune, Control Arm
FATE
Fate Therapeutics
Phase 1/2Completed96Dec 4, 2020Registry ↗
Aug 29, 2022Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunothe…
NCT04093622 · Hematological Malignancy
Genetically engineered NK cells
FATE
Fate Therapeutics
—Terminated2Apr 9, 2020Registry ↗
Nov 30, 2021The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB…
NCT01627314 · Hematologic Malignancies
ProHema-CB, Untreated CB
FATE
Fate Therapeutics
Phase 2Terminated62Mar 2016Registry ↗
Nov 22, 2021FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Sol…
NCT03319459 · HER2 Positive Gastric Cancer, Colorectal Cancer
FATE-NK100, Cetuximab
FATE
Fate Therapeutics
Phase 1Completed44May 29, 2020Registry ↗
Oct 10, 2018A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Di…
NCT02354443 · Metabolic Disorders
ProHema-CB Transplant
FATE
Fate Therapeutics
Phase 1Terminated1Dec 2016Registry ↗
Oct 10, 2018A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies
NCT02354417 · Hematologic Malignancies
Biological: ProHema-CB
FATE
Fate Therapeutics
Phase 1Terminated3Dec 2016Registry ↗
Sep 12, 2016Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
NCT01527838 · Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease
Single FT1050 treated UCB unit
FATE
Fate Therapeutics
Phase 1Completed10Oct 2013Registry ↗

24 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:15 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances